OncoDaily Medical Journal is pleased to announce the call for article submissions for the “Myeloma 2024″ Special Series, co-chaired by leading experts Dr. Dickran Kazandjian and Dr. Claudio Cerchione. This series aims to inform and guide clinical practice, with a focus on practical applications and innovative approaches in the management of myeloma.

Focus Areas for Article Submission:

• Epidemiology of Plasma Cell Disorders 
• Treatment of Newly Diagnosed Multiple Myeloma (NDMM)
• Paradigm Changes in Non-Transplant NDMM Treatment
• Smoldering Myeloma: Review of current evidence—Is early treatment warranted?
• Bispecific T Cell Engagers: Current FDA-approved therapies and what’s on the horizon.
• CAR-T Therapy: Role in relapsed/refractory multiple myeloma and its potential in frontline treatment.
• T(11;14) and New Targeted Therapies in RRMM
• Global Perspectives on Multiple Myeloma Treatment: Insights from different regions.
• New Biomarkers of Response: The role of mass spectrometry in clinical practice.
• Minimal Residual Disease (MRD) Testing in 2024

Submission Deadline: August 30, 2025!
For detailed submission guidelines or inquiries, please contact us at editorial@oncodailyjournal.com.